New rivastigmine patch put to the test against market leader
NCT ID NCT07464340
First seen Mar 15, 2026 · Last updated May 23, 2026 · Updated 10 times
Summary
This study compared a new rivastigmine skin patch to the standard Exelon patch in 68 healthy adults. Researchers measured how much drug entered the blood and how well the patch stuck to the skin over 24 hours. The goal was to see if the new patch works just as well as the approved one.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIOEQUIVALENCE STUDY IN HEALTHY SUBJECTS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Instituto de Ciências Farmacêuticas de Estudos e Pesquisas
Aparecida de Goiânia, Goiás, 74935-530, Brazil
Conditions
Explore the condition pages connected to this study.